VOCABRIA 30 MG — DIN 02497204
CABOTEGRAVIR (CABOTEGRAVIR SODIUM) : 30 MG · VIIV HEALTHCARE ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is VOCABRIA?
VOCABRIA 30 MG contains CABOTEGRAVIR (CABOTEGRAVIR SODIUM) : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02497204, held by VIIV HEALTHCARE ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Sep-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VOCABRIA used for?
VOCABRIA (cabotegravir tablets), in combination with EDURANT (rilpivirine tablets), is indicated as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA; oral bridging therapy for missed CABENUVA injections. CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cabotegravir cost around the world?
Cabotegravir is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Italy | ex-factory (classe H) | 4 | 4 | EUR███.██ |
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 1 | 2 | BRL███.██ |
| Czechia | max producer price (ex-factory) | 1 | 2 | CZK███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
16 pack listings across 14 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Cabotegravir pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cabotegravir in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Cabotegravir — 2 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| VIIV HEALTHCARE ULC | 2 | 2 | APRETUDE, VOCABRIA | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | VOCABRIA: Supplied in white HDPE bottles with child-resistant closures. Each bottle contains 30 film-coated tablets. CABENUVA: Supplied as 2 mL and 3 mL dosing kits. Each kit contains cabotegravir extended release injectable suspension (200 mg/mL) and rilpivirine extended release injectable suspension (300 mg/mL). 2 mL CABENUVA Kit: One 2 mL single-dose vial of cabotegravir (400 mg) and one 2 mL single-dose vial of rilpivirine (600 mg). 3 mL CABENUVA Kit: One 3 mL single-dose vial of cabotegravir (600 mg) and one 3 mL single-dose vial of rilpivirine (900 mg). Each 2 mL and 3 mL dosing kit also contains 2 syringes, 2 vial adaptors, and 2 needles for intramuscular injection (23-gauge, 1½ inch). |
| Storage | VOCABRIA: Store up to 30°C. CABENUVA: Store in refrigerator at 2°C to 8°C in the original carton. Do not freeze. Vials may remain at room temperature (not to exceed 25°C) for up to 6 hours; do not put back into the refrigerator. If not used within 6 hours, they must be discarded. Once drawn into syringes, injections should be administered as soon as possible, but may remain in the syringe for up to 2 hours. Filled syringes should not be refrigerated. If not used within 2 hours, they must be discarded. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Cabotegravir |
|---|---|
| ATC code | J05AJ04 |
| AHFS class | 08:18.08.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02497204 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2497204 |
| Brand name | VOCABRIA |
| Generic / active ingredient | CABOTEGRAVIR (CABOTEGRAVIR SODIUM) : 30 MG |
| Market authorization holder | VIIV HEALTHCARE ULC |
| Health Canada schedule | Prescription |
| ATC code | J05AJ04 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AJ |
| Current status | MARKETED |
| Status date | 21-Sep-2020 |
| Original market date | 2020-09-21 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
VOCABRIA: One tablet (30 mg cabotegravir) taken orally once daily with one tablet of EDURANT (25 mg rilpivirine). This is typically used as an oral lead-in for approximately one month (at least 28 days) prior to initiating CABENUVA, or as oral bridging therapy for missed CABENUVA injections. CABENUVA: Administered by a healthcare professional as two intramuscular injections (one cabotegravir and one rilpivirine) into separate gluteal sites during the same visit. It can be administered monthly or every two months. Monthly Dosing (Initiation): Single 3 mL (600 mg) intramuscular injection of cabotegravir and a single 3 mL (900 mg) intramuscular injection of rilpivirine. Continuation injections are given one month later. Monthly Dosing (Continuation): Single 2 mL (400 mg) intramuscular injection of cabotegravir and a single 2 mL (600 mg) intramuscular injection of rilpivirine administered once monthly. Every 2-Month Dosing (Initiation): Single 3 mL (600 mg) intramuscular injection of cabotegravir and a single 3 mL (900 mg) intramuscular injection of rilpivirine. A second set of 3mL initiation injections should be administered one month later. Continuation injections are given two months after the second initiation injection. Every 2-Month Dosing (Continuation): Single 3 mL (600 mg) intramuscular injection of cabotegravir and a single 3 mL (900 mg) intramuscular injection of rilpivirine administered every two months. Missed Doses: For VOCABRIA/EDURANT tablets, if a dose is missed, take it as soon as remembered if it is more than 12 hours until the next dose. If less than 12 hours, skip the missed dose. For CABENUVA injections, adherence to the schedule is strongly recommended. If a scheduled injection is missed, patients should be clinically reassessed. Oral bridging therapy with VOCABRIA and EDURANT may be used for planned missed injections. For unplanned missed injections, resumption of injections should be clinically appropriate, potentially with re-initiation doses depending on the time since the last injection.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
VOCABRIA and CABENUVA are contraindicated in patients who are hypersensitive to cabotegravir or rilpivirine or to any ingredient in the formulations. VOCABRIA is contraindicated with strong inducers of UGT1A1 or UGT1A9, including anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, and phenytoin) and antimycobacterials (rifampin, rifapentine). CABENUVA is contraindicated with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, and phenytoin), antimycobacterials (rifabutin, rifampin, rifapentine), systemic dexamethasone (more than a single-dose), and St. John's wort (Hypericum perforatum). Use of CABENUVA with rifabutin is also contraindicated.
Warnings and precautions
As with other antiretroviral drugs, therapy should be initiated by a healthcare professional experienced in the management of HIV infection. VOCABRIA and CABENUVA should not be used in patients with known or suspected resistance to cabotegravir or rilpivirine. Baseline archived RPV RAMs, in combination with other factors (HIV-1 subtype A6/A1, and/or ≥ BMI 30 kg/m²) are associated with an increased risk of virologic failure. Patients receiving VOCABRIA or CABENUVA may still develop opportunistic infections and other complications of HIV infection. Depressive disorders (including depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, and suicidal ideation) have been reported. Cases of hepatotoxicity, presenting as serum transaminase elevations, have been reported. Monitoring of liver chemistries is recommended. Residual concentrations of cabotegravir and rilpivirine injections may remain in the systemic circulation for prolonged periods (up to 12 months or longer). Concomitant use with other drugs may result in significant drug interactions leading to loss of therapeutic effect or viral resistance. Serious post-injection reactions (dyspnea, bronchospasm, agitation, abdominal cramping, rash/urticaria, dizziness, flushing, sweating, oral numbness, presyncope, changes in blood pressure, and pain) have been reported. Hypersensitivity reactions, including severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), have been reported. Administer oral lead-in dosing to identify patients at risk of hypersensitivity reactions.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APRETUDE | 30 MG | TABLET | VIIV HEALTHCARE ULC | MARKETED | 02547465 |
2 · Same class — other molecules in ATC J05AJ
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dolutegravir | TIVICAY | 4 | 2 | Yes |
| Raltegravir | ISENTRESS · ISENTRESS HD | 4 | 2 | Yes |
| Cabotegravir | APRETUDE · VOCABRIA | 2 | 2 | Yes |
| Elvitegravir | VITEKTA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VOCABRIA called?
Also recorded in Canada as: CABOTEGRAVIR (GLOBAL), CABOTEGRAVIR SODIUM (US), CABOTEGRAVIR SODIUM (UK), APRETUDE (US), APRETUDE (EU).
The same molecule, Cabotegravir, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APRETUDE | Latin | Brazil |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.